Once-weekly subcutaneous injections of semaglutide (Ozempic, Novo Nordisk) reduced alcohol cravings and consumption in adults with alcohol use disorder (AUD), findings from a small phase 2 placebo-controlled trial showed. The findings add to preclinical, observational, and pharmacoepidemiology evidence suggesting that the glucagon-like peptide 1 receptor agonist (GLP-1 RA) and similar medications may reduce alcohol intake …
Leave a Comment Leave a Comment
